Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1-Reference-Cited by-同舟云学术

Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1

Published:2023-12-15 Issue: Volume:18 Page:
ISSN:1758-3764
Container-title:European Cardiology Review
language:en
Short-container-title:Eur Cardiol

Author:

Ho Tri Huynh Quang¹^ORCID,Ton Minh That²,Nguyen Viet Lan³,Pham Hung Manh⁴,Hoang Sy Van⁵^ORCID,Vo Nhan Thanh⁶,Nguyen Thai Quoc³,Pham Linh Tran³,Mai Ton Duy⁷^ORCID,Nguyen Thang Huy⁸^ORCID

Affiliation:

1. Surgical Intensive Care Unit, Heart Institute, Ho Chi Minh City, Vietnam

2. Tam Duc Heart Hospital, Ho Chi Minh City, Vietnam

3. Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam

4. Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam; Hanoi Medical University, Hanoi, Vietnam

5. Cardiovascular Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

6. Cardiovascular Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; Cardiovascular Center, Vinmec Hospital, Ho Chi Minh City, Vietnam

7. Hanoi Medical University, Hanoi, Vietnam; Stroke Center, Bach Mai Hospital, Hanoi, Vietnam; VNU-University of Medicine and Pharmacy, Hanoi, Vietnam

8. Cerebrovascular Disease Department, People’s 115 Hospital, Ho Chi Minh City, Vietnam; Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

Abstract

In Asia, especially Vietnam, AF is a common arrhythmia and is linked to a higher risk of stroke and systemic embolism. Anticoagulation therapy for stroke prevention in AF patients can result in bleeding complications. To effectively manage AF, adopting appropriate anticoagulation and addressing modifiable risk factors are crucial. Vietnamese clinicians are particularly interested in non-vitamin K antagonist oral anticoagulants (NOACs), a recent development in AF treatment. However, the lack of head-to-head trials comparing NOACs makes selecting a specific NOAC challenging. This review aims to provide a comprehensive overview of the available clinical evidence on NOACs for stroke prevention in AF to assist clinicians in making informed decisions and improving treatment outcomes in patients with AF. The first part of this review will present the current landscape of AF in Vietnam, focusing on AF prevalence and highlighting gaps in clinical practice. Furthermore, this part extensively discusses the anticoagulation strategy for both primary and secondary stroke prevention in AF.

Publisher

Radcliffe Media Media Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference72 articles.

1. Elliott AD, Middeldorp ME, Van Gelder IC, et al. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol 2023;20:404–17. https://doi.org/10.1038/s41569-022-00820-8; PMID: 36600003.

2. Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract 2018;72:e13070. https://doi.org/10.1111/ijcp.13070; PMID: 29493854.

3. Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest 2018;153:453–66. https://doi.org/10.1016/j.chest.2017.10.001; PMID: 29017957.

4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N–9N. https://doi.org/10.1016/s0002-9149(98)00583-9; PMID: 9809895.

5. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996;27:1760–4. https://doi.org/10.1161/01.str.27.10.1760; PMID: 8841325.